

See “Effect of elemental diet combined with infliximab dose escalation in patients with Crohn’s disease with loss of response to infliximab: CERISIER trial” on page 494.

Supplementary Table 1. Adverse Events

	IFX mono group (n=6)	ED+IFX group (n=14)
Summary of adverse events		
Study drug-related adverse events		
Death	0	0
Serious adverse events	0	0
Adverse events leading to treatment discontinuation	1 (16.7)	0
Common adverse events		
Infections and infestations		
Influenza	-	1 (7.1)
Upper respiratory tract infection	2 (33.3)	-
Pharyngitis	1 (16.7)	-
Common cold	1 (16.7)	6 (42.9)
Herpes labialis	-	1 (7.1)
General disorders and administration site conditions		
Chills	-	1 (7.1)
Pyrexia	-	3 (21.4)
Malaise	2 (33.3)	-
Nervous system disorders		
Headache	1 (16.7)	-
Gastrointestinal disorders		
Abdominal pain	2 (33.3)	-
Cheilitis	1 (16.7)	-
Diarrhoea	2 (33.3)	-
Condition aggravated	-	1 (7.1)
Eye disorders		
Eyelid oedema	1 (16.7)	-
Conjunctivitis	1 (16.7)	-
Respiratory, thoracic and mediastinal disorders		
Epistaxis	-	1 (7.1)
Reproductive system and breast disorders		
Genital haemorrhage	-	1 (7.1)
Musculoskeletal and connective tissue disorders		
Ligament sprain	-	1 (7.1)

Values are presented as number (%). IFX, infliximab; ED, elemental diet.